The glucagon/GLP-1 dual agonist survodutide could reduce liver fat by 63%, results show. 

Boehringer Ingelheim reported positive results from two Phase III trials, which demonstrated patients lost 63% liver fat, 34% visceral fat and showed minimal lean mass change at the highest dose. 

The results demonstrate survodutide’s potential to reduce weight and improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes, and adults who were overweight or living with obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis. 

The new results follow previous data, in a 76-week trial, showing survodutide led to 16.6% weight loss from baseline. 

“Obesity is a complex disease linked to how the body manages metabolism,” said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim.  

“Excess visceral fat, which is found primarily around the abdomen, is a known contributor to metabolic dysfunction and is closely connected to impaired liver function. 

“By tackling obesity alongside visceral fat and liver fat, survodutide has the potential to redefine what a targeted weight management therapy can achieve, as we aim to address key drivers of metabolic dysfunction often associated with obesity.” 

The post GLP-1 reduces liver fat by 63%, trial results show  appeared first on Drug Discovery World (DDW).